Kura Oncology, Inc. cotiza a 9.83 USD y tiene una capitalización bursátil de $874M. En los últimos 12 meses ha facturado $77M con un margen de flujo de caja libre del -104.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes mult…
| Periodo | 2026-11 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | — | $-0.92 | $-0.85 | $-0.75 |
| Estimado | $-0.81 | $-0.49 | $-0.68 | $-0.37 |
| Sorpresa | — | -87.8% | -25.0% | -102.7% |
| Métrica | KURA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -449.9% | -38.6% | -411.3% |
| Net Margin | -412.9% | -33.6% | -379.4% |
| FCF Margin | -104.8% | -13.9% | -90.9% |
| ROE | -160.0% | -40.4% | -119.6% |
| ROA | -37.7% | -32.0% | -5.7% |
| Current Ratio | 6.06 | 2.84 | +3.22 |
| Debt / Equity | 0.06 | 0.28 | -0.22 |